High-dose chemotherapy with autologous stem cell support for the treatment of breast cancer
Institute for Clinical Systems Improvement
Record ID 32003000553
English
Authors' objectives:
This review aims to assess the available evidence on the effectiveness of high-dose chemotherapy with autologous stem cell support for the treatment of breast cancer.
Authors' recommendations:
With regard to high-dose chemotherapy with autologous stem cell support for the treatment of breast cancer, the ICSI Technology Assessment Committee finds:
There is no evidence of a survival benefit associated with high-dose chemotherapy protocols for patients with either high-risk primary or metastatic breast cancer (Conclusion Grade I).
High-dose chemotherapy protocols are associated with a greater frequency and a higher degree of severity of adverse effects compared with conventional-dose protocols. There does not appear to be a significant difference in procedure-related mortality (Conclusion Grade I).
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.icsi.org/index.asp
Year Published:
2002
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Drug Therapy
- Stem Cells
- Breast Neoplasms
Contact
Organisation Name:
Institute for Clinical Systems Improvement
Contact Address:
8009 34th Avenue South, Suite 1200, Bloomington, MN, USA. Tel: +1 952 814 7060; Fax: +1 952 858 9675
Contact Name:
icsi.info@icsi.org
Contact Email:
icsi.info@icsi.org
Copyright:
Institute for Clinical Systems Improvement (ICSI)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.